[ET Net News Agency, 25 October 2021] Sihuan Pharmaceutical Holdings Group Ltd. (00460)
said Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharm) of the group has obtained
approval for the commencement of phase III clinical trials from the Center for Drug
Evaluation of the National Medical Products Administration (NMPA) in relation to Xuanzhu
Biopharm's new drug XZP-3621, which specific indication is ALK-positive advanced non-small
cell lung cancer (NSCLC), marking the first product of Xuanzhu Biopharm in the NSCLC area
entering into key development stage.
XZP-3621 is a next generation dual inhibitor of ALK/ROS1 for the treatment of NSCLC.
(RC)